| (Values in U.S. Thousands) | Dec, 2011 | Dec, 2010 | Dec, 2009 | Dec, 2008 | Dec, 2007 |
| Sales | 11,500 | 8,260 | 2,000 | 0 | 0 |
| Sales Growth | +39.23% | +313.00% | unch | unch | unch |
| Net Income | -49,540 | -44,510 | -21,860 | -26,030 | -31,950 |
| Net Income Growth | -11.30% | -103.61% | +16.02% | +18.53% | unch |
Neurogesx (NGSX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
NEUROGESX INC., is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia, painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy. NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over other pain therapies.
Fiscal Year End Date: 12/31